Trial reportFrontiers in digital health2026
Use of a digital health solution after percutaneous coronary intervention: a randomised controlled trial.
Trial report in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05713565 (A Randomized-controlled Trial Evaluating a Digital Care Solution), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized-controlled Trial Evaluating a Digital Care Solution (Sidekick, SK-121) for Coronary Artery Disease Patients at Landspítali University Hospital
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To evaluate a multimodal digital health intervention (SK-121) as an adjunct to standard of care (SoC) to reduce the risk of recurrent cardiovascular events in patients following percutaneous coronary intervention (PCI). Methods and results: In this single-centre, randomised controlled trial of 200 patients (mean age 64.4 years; 79.5% male) who underwent PCI, patients were randomised 1:1 to receive SoC alone or SoC plus a 48-week gamified digital program focusing on lifestyle modification and remote patient monitoring (RPM). User retention and engagement were high with 84% remaining active at 24 weeks and weekly RPM completion averaging 94%. The primary endpoint was the baseline-adjusted between-group difference in the Second Manifestations of ARTerial disease, version 2 (SMART2) risk score at 6 months. These SMART2 scores did not differ between the intervention and control groups (adjusted mean difference -0.3%; 95% confidence interval -2.4% to 1.9%; Conclusion: While the intervention did not reduce the SMART2 risk score in the overall population, it significantly improved disease knowledge, short-term medication adherence, and diastolic blood pressure. The program was well-accepted and may offer prognostic benefits for overweight patients. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT05713565, NCT05713565.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.